Search Results: Repatha

Redirect to:


Evolocumab
Kamis, 2026-07-30 23:36:45

Evolocumab, sold under the brand name Repatha, is a monoclonal antibody drug. It is an immunotherapy medication for the treatment of hyperlipidemia. Evolocumab...

Click to read more »
Amgen
Senin, 2026-05-25 01:31:14

osteoporosis and bone diseases ($6.6 billion in total 2025 revenues), Repatha (evolocumab) to treat hyperlipidemia ($3.0 billion in 2025 revenues), Otezla...

Click to read more »
TrumpRx
Jumat, 2026-07-17 19:29:43

including Gonal-f, on TrumpRx. AmgenNow, a website from Amgen that offers Repatha, is additionally set to appear on TrumpRx. At its launch on February 5...

Click to read more »
Regeneron Pharmaceuticals
Sabtu, 2026-07-25 22:38:28

practices to exclude Praluent from the market and elevate Amgen's rival Repatha. On February 4, 2020, the U.S. Department of Health and Human Services...

Click to read more »
List of therapeutic monoclonal antibodies
Minggu, 2026-08-02 06:32:14

Evinacumab Evkeeza mab human angiopoietin 3 Y dyslipidemia Evolocumab Repatha mab human PCSK9 Y hypercholesterolemia Exbivirumab mab human hepatitis...

Click to read more »
PCSK9
Minggu, 2026-08-02 02:47:22

S. Food and Drug Administration (FDA) on 24 July 2015, and evolocumab (Repatha, Amgen), approved on 27 August 2015; both were also authorised in the European...

Click to read more »
List of drugs: Re
Rabu, 2026-07-15 19:32:27

abciximab. repagermanium (INN) repaglinide (INN) Repan reparixin (USAN) Repatha repifermin (INN) repirinast (INN) repotrectinib (INN) repromicin (INN)...

Click to read more »
Monoclonal antibody therapy
Minggu, 2026-08-02 04:43:38

receptor Migraine headache prevention 761077 Link[dead link] evolocumab Repatha Amgen 8/27/2015 subcutaneous fully human PCSK9 Heterozygous familial hypercholesterolemia...

Click to read more »
2017 in science
Jumat, 2026-07-31 05:25:45

March 2017. Retrieved 17 March 2017. "Landmark Outcomes Study Shows That Repatha (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk...

Click to read more »